Extended-Release Memantine Appears Safe and Effective in Alzheimer's
"Extended-release memantine in combination with a cholinesterase inhibitor ... The new high-dose extended-release memantine option is currently under review by ...
Press Release
... of an innovative, proprietary, 28 mg memantine extended-release, once-daily ... assigned to receive either 28 mg/day of memantine extended release or placebo. ...
New Data Highlights Positive Results of Namenda® (Memantine HCl) Once ...
... mg/day of memantine once-daily extended-release or placebo. ... The study also demonstrated that once-daily extended-release memantine was well tolerated. ...
New Data Highlights Positive Results Of Namenda(R) (Memantine HCl) Once ...
Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda® (memantine HCl) at the 2008 ...
New Data Highlight Positive Results Of Namenda(R) (memantine HCl) Once ...
Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 ...
Extended-Release Memantine Safe and Effective for Moderate to Severe ...
In addition, the extended-release memantine group also scored significantly ... Dr. Grossberg concluded, "Extended-release memantine is at least as efficacious ...
News - Extended-Release Memantine Safe and Effective for Moderate to ...
Extended-Release Memantine Safe and Effective for Moderate to Severe Alzheimer's Disease: Presented ... addition, the extended-release memantine group also ...
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once ...
... of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation, CHICAGO, July 30 ... that once-daily extended-release memantine was well tolerated. ...
Alzheimer's Weekly - Namenda (Memantine) : One-A-Day on the Way
... of an innovative, proprietary, 28 mg memantine extended-release, once-daily ... assigned to receive either 28 mg/day of memantine extended release or placebo. ...
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once ...
... mg/day of memantine once-daily extended-release or placebo. ... The study also demonstrated that once-daily extended-release memantine was well tolerated. ...
|
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release...
| Reuters
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily
Extended-Release Formulation
- Results Presented at ICAD 2008 Highlight Significant Improvement in
Cognitive Performance and Global Clinical Status in Patients with Alzheimer's
Disease -
CHICAGO, July 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) presented today positive Phase III data of a once-daily
extended-release formulation of Namenda(R) (memantine HCl) at the 2008
Alzheimer's Association International Conference on Alzheimer's Disease
(ICAD). The study evaluated the efficacy, safety and tolerability of an
innovative, proprietary, 28 mg once-daily extended-release formulation of
Namenda compared to placebo in outpatients with moderate to severe Alzheimer's
disease already being treated with a cholinesterase inhibitor (donepezil,
galantamine or rivastigmine).